North America Attention Deficit Hyperactivity Disorder Market

North America Attention Deficit Hyperactivity Disorder Market Size, Share & Industry Trends Analysis Report By Drug Type, By Demographics (Adults and Children), By Distribution Channel (Retail Pharmacy and Hospital Pharmacy), By Country and Growth Forecast, 2022 - 2028

Report Id: KBV-12225 Publication Date: November-2022 Number of Pages: 95
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Analysis of Market Size & Trends

The North America Attention Deficit Hyperactivity Disorder Market would witness market growth of 3.3% CAGR during the forecast period (2022-2028).

The ADHD symptoms that appear predominantly inattentive make it challenging for the sufferer to arrange or complete a task, pay close attention to specifics, or follow directions or dialogues. The individual gets easily side-tracked or overlooks small elements of daily activities. Symptoms that are predominantly hyperactive-impulsive make the sufferer fidget and speak a lot.

Long periods of stillness are challenging for these individuals. Younger children may continually jump, run, or climb. They are also highly restless and have difficulties with impulse control. Impulsive individuals may speak suddenly, seize objects from others, or interrupt others frequently. The person needs help to follow instructions or wait their turn. Impulsiveness increases the likelihood of accidents and injury for some people.

A combination presentation of ADHD makes the person exhibit both of the signs mentioned earlier in equal measure. It is possible for a person to have different types of symptoms at different stages. Nearly 11% of school-age children have ADHD, which has become a major health issue. In three out of four cases, the symptoms last throughout adulthood. Family stress, academic failure, disturbance, depression, interpersonal connection problems, substance misuse, delinquency, unintentional accidents, and work failure are just a few of the dire consequences that are linked to ADHD.

There are some common incidences that children with ADHD may continue to experience during the transition from childhood to adulthood. These symptoms include driving issues, issues relating to peers and social circumstances, high-risk sexual conduct, and substance addiction. As these symptoms make it difficult to sustain a comparatively everyday life, it has necessitated the need for ADHD treatments.

The North America region has significantly contributed to the development of ADHD therapeutics through the number of studies and research on this topic collectively. One such survey highlighted by the Environment Protection Agency of the US stated that approximately 15% of children aged 3 to 17 in the nation were suffering from some type of neurodevelopmental disorder. The disorders included learning disabilities, cerebral palsy, intellectual disability, seizures, stammering, autism, and ADHD. Among all these neurodevelopmental disorders, children with ADHD had the highest frequency.

The US market dominated the North America Attention Deficit Hyperactivity Disorder Market by Country in 2021; thereby, achieving a market value of $7 billion by 2028. The Canada market is experiencing a CAGR of 5.6% during (2022 - 2028). Additionally, The Mexico market would exhibit a CAGR of 4.7% during (2022 - 2028).

Based on Drug Type, the market is segmented into Stimulants and Non-stimulants. Based on Stimulants Type, the market is segmented into Amphetamine, Methylphenidate, Lisdexamfetamine and Dexmethylphenidate. Based on Non-stimulants Type, the market is segmented into Atomoxetine, Guanfacine, Clonidine and Others. Based on Demographics, the market is segmented into Adults and Children. Based on Distribution Channel, the market is segmented into Retail Pharmacy and Hospital Pharmacy. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Free Valuable Insights: The Global Attention Deficit Hyperactivity Disorder Market is Predict to reach $16.9 Billion by 2028, at a CAGR of 4%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eli Lilly And Company, Pfizer, Inc. (Global Blood Therapeutics, Inc.), Johnson & Johnson (Johnson & Johnson Services, Inc.), Lupin Limited, Novartis AG, Takeda Pharmaceutical Company Limited, Mallinckrodt PLC, Purdue Pharma L.P., Aytu BioPharma, Inc. and Supernus Pharmaceuticals, Inc.

Scope of the Study

Market Segments Covered in the Report:

By Drug Type

  • Stimulants
    • Amphetamine
    • Methylphenidate
    • Lisdexamfetamine
    • Dexmethylphenidate
  • Non-stimulants
    • Atomoxetine
    • Guanfacine
    • Clonidine
    • Others

By Demographics

  • Adults
  • Children

By Distribution Channel

  • Retail Pharmacy
  • Hospital Pharmacy

By Country

  • US
  • Canada
  • Mexico
  • Rest of North America

Key Market Players

List of Companies Profiled in the Report:

  • Eli Lilly And Company
  • Pfizer, Inc. (Global Blood Therapeutics, Inc.)
  • Johnson & Johnson (Johnson & Johnson Services, Inc.)
  • Lupin Limited
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Mallinckrodt PLC
  • Purdue Pharma L.P.
  • Aytu BioPharma, Inc.
  • Supernus Pharmaceuticals, Inc.
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo